v3.25.2
REVENUE AGREEMENTS (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 15, 2024
May 15, 2024
Jun. 06, 2023
May 31, 2025
Apr. 17, 2025
Nov. 30, 2024
Jul. 31, 2024
Jun. 30, 2023
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Support service                 $ 1,656   $ 214 $ 4,722 $ 1,451  
Revenues                 17,261   5,433 18,292 5,899  
Sale of IP [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contract liability                 122 $ 130   122   $ 130
Revenue recognized in coonection with aggreement                       8    
Support service                       200    
Revenues                 16,000   4,800 16,000 4,800  
Continuing services [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 14   21 32 43  
License revenue [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 717     1,577    
Padagis Israel Pharmaceuticals Ltd [Member] | Sale of IP [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                           3,800
License Agreements With Galderma [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                       433 723  
Exclusive License Agreement With Searchlight Pharma Inc [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Maximum upfront payments and regulatory approval milestone payments per product     $ 11,000         $ 500            
Description and terms     over a fifteen-year term that is renewable for subsequent five-year periods.                      
Contract liability                 40 64 $ 78 40 78 $ 64
Exclusive License Agreement With Searchlight Pharma Inc [Member] | Continuing services [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                       24 42  
Exclusive License Agreement With Searchlight Pharma Inc [Member] | License revenue [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                       $ 750 $ 0  
Purchase Agreement With Beimei [Member] | Intellectual Property [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Maximum upfront payments and regulatory approval milestone payments per product   $ 10,000                        
Royalty Income, Nonoperating   $ 5,000                        
Revenue recognized in coonection with aggreement           $ 1,500 $ 2,000              
Termination Agreement [Member] | Padagis Israel Pharmaceuticals Ltd [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Consideration for agreement $ 4,250                          
Royalties payment percentage 2.00%                          
Mayne Pharma Group Limited [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Consideration for agreement       $ 10,000 $ 16,000       10,000 $ 6,000        
Revenues                 16,000          
Revenues not yet been received                 $ 6,000